LHRH was selected for the development cytotoxic conjugates based on the presence of its receptor in various tumoral tissues including ovarian, endometrial, colorectal, pancreatic, bladder and prostate cancer as well as in glioblastoma [13, 28-30, 51-53]. Here, GNRH1 is linked to prostate cancer.